(Q38238948)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Adverse reactions to biologic agents and their medical management (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Denis Comte

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

François Spertini

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

language of work or name

English

0 references

publication date

12 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

612-627

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25112605%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2014.123

12 March 2020

exact match

0 references

cites work

Adverse side-effects to biological agents

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Unique aspects of supportive care using monoclonal antibodies in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Anaphylaxis: lessons from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Mouse and human neutrophils induce anaphylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunog

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tuberculosis associated with therapy against tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The risk of infections with biologic therapies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Mycobacterial diseases and antitumour necrosis factor therapy in USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tuberculosis reactivation during immunosuppressive therapy in rheumatic diseases: diagnostic and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

B cell non-Hodgkin's lymphoma: rituximab safety experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Infections and biologic therapy in rheumatoid arthritis: our changing understanding of risk and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tumor necrosis factor inhibition and invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Effect of IL-17A blockade with secukinumab in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Emergence of the Th17 pathway and its role in host defense.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Integrated safety in tocilizumab clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of extended treatment with anakinra in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Infections in patients with rheumatoid arthritis treated with biologic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of Herpes zoster in patients with psoriasis treated with biologic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Cryoglobulinemia vasculitis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Dermatological complications and safety of anti-TNF treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Autoimmune diseases induced by biological agents: a double-edged sword?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Autoimmune Diseases Induced by TNF-Targeted Therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Biologics-induced autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-induced thrombocytopenia: a cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Case reports of heart failure after therapy with a tumor necrosis factor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Impact of obesity on plasma natriuretic peptide levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Major cardiovascular events associated with anti-IL 12/23 agents: a tale of two meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Incidence of extraarticular rheumatoid arthritis in Olmsted County, Minnesota, in 1995-2007 versus 1985-1994: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The safety of biologic therapies in RA-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Methotrexate pulmonary toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Interstitial lung disease in rheumatoid arthritis: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

[A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The incidence of gastrointestinal perforations among rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Role of interleukin-6 signalling in glucose and lipid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-induced vasculitis: A case report and review of the medical published work

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Inflammatory demyelinating events following treatment with anti-tumor necrosis factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Multiple sclerosis onset during etanercept treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Protective effect of A/H1N1 vaccination in immune-mediated disease--a prospectively controlled vaccination study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-treated patients have a poor response to influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to the 23 valent pneumococcal polysaccharide vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Succinct review of the new VTE prevention and management guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rapid IgE desensitization is antigen specific and impairs early and late mast cell responses targeting FcεRI internalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Allergy to monoclonal antibodies: cutting-edge desensitization methods for cutting-edge therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Adverse reactions to TNF-α inhibitors in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor α antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Drug-Specific Th2 Cells and IgE Antibodies in a Patient with Anaphylaxis to Rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Adverse effects of biologics: a network meta-analysis and Cochrane overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Herpes zoster in patients treated with biologicals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Cytokine imbalance with increased production of interferon-α in psoriasiform eruptions associated with antitumour necrosis factor-α treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-induced acute thrombocytopenia: an underappreciated entity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Successful use of tocilizumab in a patient with rheumatoid arthritis following severe pancytopenia during etanercept therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Severe pancytopenia following etanercept administration in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Development of psoriasis after B cell depletion with rituximab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Onset of psoriasis following treatment with tocilizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Paradoxical reactions to targeted biological treatments: A way to treat and trigger?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-induced vasculitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rituximab-induced leukocytoclastic vasculitis: a case report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Demyelinating events in rheumatoid arthritis after drug exposures

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Optic neuritis associated with tumor necrosis factor-alfa antagonists for the treatment of psoriasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Rheumatoid arthritis and herpes zoster: risk and prevention in those treated with anti-tumour necrosis factor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Adalimumab desensitization after anaphylactic reaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2014.123

Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic

31 March 2020

1 reference

12 December 2020

Monoclonal antibodies, immunogenicity, and associated infusion reactions

1 reference

12 December 2020

Tocilizumab-induced erythroderma.

1 reference

12 December 2020

How tumour necrosis factor blockers interfere with tuberculosis immunity.

1 reference

12 December 2020

Immunological protection against tuberculosis.

1 reference

12 December 2020

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis

1 reference

12 December 2020

Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.

1 reference

12 December 2020

Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy.

1 reference

12 December 2020

Adalimumab-associated multiple sclerosis

1 reference

12 December 2020

The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis

1 reference

12 December 2020

Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.

1 reference

12 December 2020

Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.

1 reference

12 December 2020

Successful adalimumab desensitization after generalized urticaria and rhinitis

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis

1 reference

12 December 2020

Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents.

1 reference

12 December 2020

Tumor necrosis factor-alpha blockade and the risk of vasculitis

1 reference

12 December 2020

Arterial thrombosis with anti-phospholipid antibodies induced by infliximab

1 reference

12 December 2020